FOLH1 and prostate cancer: In 2016, [68Ga]Ga-PSMA-11-based PET imaging was proposed as a key technology for individualized radiotherapy in prostate cancer patients as it was reported that the therapeutic strategy was changed in 50.8% of the cases [18].